STORLINO, GIUSEPPINA
 Distribuzione geografica
Continente #
NA - Nord America 746
EU - Europa 302
AS - Asia 113
Totale 1.161
Nazione #
US - Stati Uniti d'America 746
IT - Italia 195
CN - Cina 76
SE - Svezia 63
GB - Regno Unito 14
IN - India 14
SG - Singapore 12
VN - Vietnam 10
BE - Belgio 7
FR - Francia 7
CZ - Repubblica Ceca 6
DE - Germania 5
IE - Irlanda 2
BG - Bulgaria 1
ES - Italia 1
NL - Olanda 1
SA - Arabia Saudita 1
Totale 1.161
Città #
Fairfield 108
Bari 102
Chandler 90
Ashburn 80
Woodbridge 79
Nyköping 54
Seattle 52
Houston 43
Wilmington 43
Ann Arbor 34
Cambridge 34
New York 23
Grumo Appula 21
Roxbury 14
Beijing 13
Pune 13
Des Moines 11
Lawrence 11
Trani 11
Dong Ket 10
Nanjing 10
Inglewood 8
Rome 8
Brussels 7
Dearborn 6
Guangzhou 6
San Diego 6
Singapore 6
Brno 5
Changsha 5
Brooklyn 4
Falls Church 4
Hefei 4
Jiaxing 3
London 3
Los Angeles 3
Novara 3
Paris 3
Randazzo 3
Shanghai 3
Shenyang 3
Boardman 2
Bologna 2
Dublin 2
Jinan 2
Kunming 2
Munich 2
Nanchang 2
Redwood City 2
Tianjin 2
Turin 2
Vercelli 2
Washington 2
Wuhan 2
Amsterdam 1
Bhopal 1
Boydton 1
Florence 1
Hebei 1
Heze 1
Islington 1
Jian 1
Kilburn 1
Milan 1
Ningbo 1
Noicattaro 1
Olomouc 1
Prescot 1
Qingdao 1
Quanzhou 1
Redmond 1
Sofia 1
Taranto 1
Tiantai Chengguanzhen 1
Xian 1
Zhengzhou 1
Zibo 1
Totale 998
Nome #
Impairment of bone remodeling in LIGHT/TNFSF14-deficient mice 141
Effects of sweet cherry polyphenols on enhanced osteoclastogenesis associated with childhood obesity 120
Irisin serum levels are positively correlated with bone mineral status in a population of healthy children 112
LIGHT/TNFSF14 as a new biomarker of bone disease in multiple myeloma patients experiencing therapeutic regimens 107
Irisin and Bone: From Preclinical Studies to the Evaluation of Its Circulating Levels in Different Populations of Human Subjects 106
A role of light as potential biomarker for progression of smoldering to symptomatic multiple myeloma 76
null 65
Myokines and Osteokines in the Pathogenesis of Muscle and Bone Diseases 61
null 57
Irisin Correlates Positively With BMD in a Cohort of Older Adult Patients and Downregulates the Senescent Marker p21 in Osteoblasts 57
null 56
Shedding “LIGHT” on the Link between Bone and Fat in Obese Children and Adolescents 54
In Reply to the Letter to the Editor: Involvement of Irisin in Age-Related Osteoporosis and Its Inhibitory Effect on the Senescent Marker p21 in Osteoblasts 42
LIGHT as regulator of bone homeostasis during osteolytic bone metastasis formation in non-small cell lung cancer patients 39
LIGHT/TNFSF14 regulates estrogen deficiency-induced bone loss 29
Irisin Serum Levels and Skeletal Muscle Assessment in a Cohort of Charcot-Marie-Tooth Patients 23
Irisin Prevents Disuse-Induced Osteocyte Apoptosis 22
Antidepressant Effect of Intermittent Long‐Term Systemic Administration of Irisin in Mice 20
Impact of 10-day bed rest on serum levels of irisin and markers of musculoskeletal metabolism 14
Irisin Modulates Inflammatory, Angiogenic, and Osteogenic Factors during Fracture Healing 13
Irisin Protects against Loss of Trabecular Bone Mass and Strength in Adult Ovariectomized Mice by Stimulating Osteoblast Activity 10
Once-Daily Subcutaneous Irisin Administration Mitigates Depression- and Anxiety-like Behavior in Young Mice 9
Short-Term Irisin Treatment Enhanced Neurotrophin Expression Differently in the Hippocampus and the Prefrontal Cortex of Young Mice 9
Irisin prevents trabecular bone damage and tumor invasion in a mouse model of multiple myeloma 9
Time-dependent unloading effects on muscle and bone and involvement of FNDC5/irisin axis 8
LIGHT/TNFSF14 Promotes Osteolytic Bone Metastases in Non-small Cell Lung Cancer Patients 1
Totale 1.260
Categoria #
all - tutte 5.466
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.466


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020243 19 12 8 19 16 18 26 47 31 26 10 11
2020/2021331 31 15 15 10 26 20 43 51 61 20 20 19
2021/2022160 24 1 1 1 14 19 5 2 26 8 20 39
2022/2023228 15 34 20 13 16 32 8 30 35 1 9 15
2023/2024176 15 25 12 9 11 50 12 7 1 15 3 16
2024/202560 60 0 0 0 0 0 0 0 0 0 0 0
Totale 1.260